JP2021522276A5 - - Google Patents
Info
- Publication number
- JP2021522276A5 JP2021522276A5 JP2020560316A JP2020560316A JP2021522276A5 JP 2021522276 A5 JP2021522276 A5 JP 2021522276A5 JP 2020560316 A JP2020560316 A JP 2020560316A JP 2020560316 A JP2020560316 A JP 2020560316A JP 2021522276 A5 JP2021522276 A5 JP 2021522276A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- membered
- pharmaceutically acceptable
- optionally substituted
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024004034A JP7838004B2 (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664592P | 2018-04-30 | 2018-04-30 | |
| US62/664,592 | 2018-04-30 | ||
| PCT/US2019/029778 WO2019213005A1 (en) | 2018-04-30 | 2019-04-30 | Small molecule degraders of polybromo-1 (pbrm1) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024004034A Division JP7838004B2 (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522276A JP2021522276A (ja) | 2021-08-30 |
| JP2021522276A5 true JP2021522276A5 (https=) | 2022-05-09 |
| JPWO2019213005A5 JPWO2019213005A5 (https=) | 2022-05-09 |
| JP7471232B2 JP7471232B2 (ja) | 2024-04-19 |
Family
ID=68386081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560316A Active JP7471232B2 (ja) | 2018-04-30 | 2019-04-30 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
| JP2024004034A Active JP7838004B2 (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024004034A Active JP7838004B2 (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11771697B2 (https=) |
| EP (1) | EP3787747A4 (https=) |
| JP (2) | JP7471232B2 (https=) |
| AU (1) | AU2019261938B2 (https=) |
| CA (1) | CA3093405C (https=) |
| WO (1) | WO2019213005A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN119751456A (zh) | 2018-04-16 | 2025-04-04 | C4医药公司 | 螺环化合物 |
| US12371426B2 (en) * | 2018-04-26 | 2025-07-29 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as SMARCA2/4 degraders |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| KR102672549B1 (ko) * | 2018-09-30 | 2024-06-10 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 이소인돌린계 화합물, 이의 제조 방법, 약학 조성물 및 용도 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| JP2023511471A (ja) * | 2019-10-28 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二官能性化合物 |
| EP4051674A1 (en) * | 2019-10-29 | 2022-09-07 | F. Hoffmann-La Roche AG | Bifunctional compounds for the treatment of cancer |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| BR112022012410A2 (pt) * | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| AU2021205326A1 (en) * | 2020-01-10 | 2022-07-21 | Amgen Inc. | SMARCA2-VHL degraders |
| US20240000950A1 (en) * | 2020-08-07 | 2024-01-04 | Cornell University | Therapeutic cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and using them |
| WO2022099117A1 (en) * | 2020-11-06 | 2022-05-12 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
| CA3199652A1 (en) * | 2020-11-20 | 2022-05-27 | Matthew Netherton | Compounds and uses thereof |
| CA3196965A1 (en) * | 2020-11-20 | 2022-05-27 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| CA3217892A1 (en) * | 2021-05-03 | 2022-11-10 | Joel Mcintosh | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| US11993599B2 (en) | 2021-08-09 | 2024-05-28 | Genentech, Inc. | Therapeutic compounds |
| JP2025523393A (ja) | 2022-06-06 | 2025-07-23 | シーフォー セラピューティクス， インコーポレイテッド | 二環式置換グルタルイミドセレブロンバインダー |
| TW202515566A (zh) | 2023-06-14 | 2025-04-16 | 瑞典商阿斯特捷利康公司 | Ｓｍａｒｃａ２降解劑及其用途 |
| MX2025015084A (es) | 2023-06-14 | 2026-02-03 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| WO2025106472A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2026061475A1 (zh) * | 2024-09-19 | 2026-03-26 | 标新生物医药科技(上海)有限公司 | 含有芳基取代杂芳基的双功能蛋白降解剂及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| AU2017246452C1 (en) * | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| CN109790143A (zh) * | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CA3036841A1 (en) * | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet protein degraders |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| US20190300521A1 (en) | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US12371426B2 (en) * | 2018-04-26 | 2025-07-29 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as SMARCA2/4 degraders |
-
2019
- 2019-04-30 WO PCT/US2019/029778 patent/WO2019213005A1/en not_active Ceased
- 2019-04-30 AU AU2019261938A patent/AU2019261938B2/en active Active
- 2019-04-30 CA CA3093405A patent/CA3093405C/en active Active
- 2019-04-30 US US17/042,634 patent/US11771697B2/en active Active
- 2019-04-30 JP JP2020560316A patent/JP7471232B2/ja active Active
- 2019-04-30 EP EP19797003.1A patent/EP3787747A4/en active Pending
-
2024
- 2024-01-15 JP JP2024004034A patent/JP7838004B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522276A5 (https=) | ||
| JPWO2019213005A5 (https=) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2020520926A5 (https=) | ||
| JP2021523112A5 (https=) | ||
| JP2019520417A5 (https=) | ||
| JP2018535963A5 (https=) | ||
| WO2018013597A4 (en) | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors | |
| JP2012236838A5 (https=) | ||
| JPWO2019165229A5 (https=) | ||
| JP2021523225A5 (https=) | ||
| JP2012507522A5 (https=) | ||
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2019502650A5 (ja) | 抗ＥｒｂＢ２抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用 | |
| JP2021522237A5 (https=) | ||
| JP2017500334A5 (https=) | ||
| JPWO2020252589A5 (https=) | ||
| AU2022366992A1 (en) | Integrin inhibitors and uses thereof in combination with other agents | |
| FI3976581T3 (fi) | [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat | |
| JPWO2020086732A5 (https=) | ||
| JPWO2019213445A5 (https=) | ||
| US20200270200A1 (en) | Deuterated compounds and uses thereof | |
| JP2025516359A5 (https=) | ||
| WO2020166592A1 (ja) | ヘミアスタリン誘導体とその抗体薬物複合体 | |
| JPWO2019246300A5 (https=) |